KRT6A and lung adenocarcinoma: In the prognostic analysis of disease-specific survival (DSS), CYP4B1 (p = 0.000249), FAM83A (p = 5.69E-05), and KRT6A (p = 0.001235) had the highest effect on the disease-specific survival of lung adenocarcinoma patients.